Spironolactone enhances the beneficial effect of aliskiren on cardiac structural and electrical remodeling in TGR(mRen2)27 rats

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 16, Issue 3, 2015, Pages 488-494

  De Mello, Walmor C ^a  

^a UNIVERSITY OF PUERTO RICO SCHOOL OF MEDICINE   (Puerto Rico)

Author keywords

aliskiren; cardiac; remodeling; spironolactone; TGR(mRen2)27 rat

Indexed keywords

ALISKIREN; SPIRONOLACTONE; AMIDE; FUMARIC ACID DERIVATIVE; RENIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR PARAMETERS; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; ECHOCARDIOGRAPHY; HEART EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE VOLUME; HISTOLOGY; HYPERTENSION; LEFT VENTRICLE POSTERIOR WALL THICKNESS; MALE; MONOTHERAPY; NONHUMAN; RAT; ANATOMY AND HISTOLOGY; ANIMAL; BLOOD PRESSURE; CORONARY BLOOD VESSEL; DRUG EFFECTS; FIBROSIS; GENETICS; HEART; HEART MUSCLE CONDUCTION SYSTEM; HEART VENTRICLE REMODELING; INTRAPERITONEAL DRUG ADMINISTRATION; PATHOLOGY; REST; SYSTOLE; TRANSGENIC RAT;

AMIDES; ANIMALS; BLOOD PRESSURE; CORONARY VESSELS; ECHOCARDIOGRAPHY; FIBROSIS; FUMARATES; HEART; HEART CONDUCTION SYSTEM; INJECTIONS, INTRAPERITONEAL; MALE; RATS, TRANSGENIC; RENIN; REST; SPIRONOLACTONE; SYSTOLE; VENTRICULAR REMODELING;

EID: 84950318825     PISSN: 14703203     EISSN: 17528976     Source Type: Journal    
DOI: 10.1177/1470320313497818     Document Type: Article

References (29)

1. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709-717.
2. Zannad F, Alla F, Dousset B, et al. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: Insights from the Randomized Aldosterone Evaluation Study (RALES). Rales Investigators. Circulation 2000; 102: 2700-2706.
3. Robert V, Hermes C, Silvestre JS, et al. Angiotensin AT1 receptor subtype as a cardiac target of aldosterone: Role of aldosterone-salt induced fibrosis. Hypertension 1999; 33: 981-986.
4. Milliez P, Girerd X, Plouin PF, et al. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005; 45: 1243-1248.
5. Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2005; 364, 11-21.
6. Gekle M, Grossmann C,. Actions of aldosterone in the cardiovascular system: The good, the bad, and the ugly? Pflugers Arch 2009; 458: 231-246. Epub ahead of print 19 2008.
7. Ouvrard-Pascaud A, Sainte-Marie Y, Bénitah JP, et al. Conditional mineralocorticoid receptor expression in the heart leads to life-threatening arrhythmias. Circulation 2005; 111: 3025-3033.
8. Zhao W, Ahokas RA, Weber KT, et al. ANG II-induced cardiac molecular and cellular events: Role of aldosterone. Am J Physiol Heart Circ Physiol 2006; 291: H336-H343.
9. Swedberg K, Zannad F, McMurray JJ, et al.; EMPHASIS-HF Study Investigators. Eplerenone and atrial fibrillation in mild systolic heart failure: Results from the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And Survival Study in Heart Failure) Study. J Am Coll Cardiol 2012; 59: 1598-1603.
10. Konishi A, Tazawa C, Miki Y, et al. The possible roles of mineralocorticoid receptor and 11beta-hydroxysteroid dehydrogenase type 2 in cardiac fibrosis in the spontaneously hypertensive rat. Steroid Biochem Mol Biol 2003; 85: 439-442.
11. Takeda AN, Pinon GM, Bens M, et al. The synthetic androgen methyltrienolone (r1881) acts as a potent antagonist of the mineralocorticoid receptor. Mol Pharmacol 2007; 71: 473-482.
12. Ohtani T, Ohta M, Yamamoto K, et al. Elevated cardiac tissue level of aldosterone and mineralocorticoid receptor in diastolic heart failure: Beneficial effects of mineralocorticoid receptor blocker. Am J Physiol Regul Integr Comp Physiol 2 007; 292: R946-R954.
13. Mullins JJ, Peters J, Ganten D,. Fulminant hypertension in transgenic rats harbouring the mouse Ren-2 gene. Nature 1990; 3: 541-544.
14. Bader M, Zhao Y, Sander M, et al. Role of tissue renin in the pathophysiology of hypertension in TGR(mRen2)27 rats. Hypertension 1992; 19: 681-686.
15. Moriuchi A, Brosnihan KB, Kumagai H, et al. CM Mechanisms of hypertension in transgenic rats expressing the mouse Ren-2 gene. Am J Physiol 1994; 266: R1273-R1279.
16. Mullins JJ, Peters J,. Ontogenetic regulation of mouse Ren-2d renin gene in transgenic hypertensive rats TGR(mRen2)27. Am J Physiol 1993; 265: E699-E707.
17. Campbell DJ, Rong P, Kladis A, et al. Angiotensin and bradykinin peptides in the TGR(mRen2) 27 rat. Hypertension 1995; 25: 1014-1020.
18. Sander M, Bader M, Diavidani B, et al. The role of the adrenal gland in hypertensive transgenic rat TGR(mRen2)27. Endocrinology 1992; 131: 807-814.
19. Whaley-Connell A, Habibi J, Cooper SA, et al. Effect of renin inhibition and AT1R blockade on myocardial remodeling in the transgenic Ren2 rat. Am J Physiol Endocrinol Metab 2008; 295: E103-E109.
20. Rudy Y, Quan WL,. A model study of the effects of discrete cellular structure on the electrical propagation in cardiac muscle. Circ Res 1987; 61: 815-823.
21. De Mello WC,. Beneficial effect of eplerenone on cardiac remodelling and electrical properties of the failing heart. Renin Angiotensin Aldosterone Syst 2006; 7: 40-46.
22. De Jong S, van Veen AB, van Rijen HVM, et al. Fibrosis and cardiac arrhythmias. J Cardiovasc Pharmacol 2011; 57: 630-638.
23. Brilla CG, Matsubara LS, Weber KT,. Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism. J Mol Cell Cardiol 1993; 25: 563-575.
24. De Mello WC,. Heart failure: How important is cellular sequestration? The role of the renin-angiotensin-aldosterone system. J Mol Cell Cardiol 2004; 37: 431-438.
25. De Mello WC, Gerena Y,. Eplerenone inhibits the intracrine and extracellular actions of angiotensin II on the inward calcium current in the failing heart. On the presence of an intracrine renin angiotensin aldosterone system. Regul Pept 2008; 29; 151: 54-60. Epub ahead of print 8 2008. DOI: 10.1016/j.regpep.2008.06.003.
26. Yasuda N, Akazawa H, Qin Y, et al. A novel mechanism of mechanical stress-induced angiotensin II type 1-receptor activation without the involvement of angiotensin II. Naunyn Schmiedeberg's Arch Pharmacol 2008; 377: 393-399.
27. De Mello WC,. Mechanical stretch reduces the effect of angiotensin II on potassium current in cardiac ventricular cells of adult Sprague Dawley rats. On the role of AT1 receptors as mechanosensors. J Am Soc Hypertens 2012; 6: 369-374.
28. De Mello W, Rivera M, Rabell A, et al. Aliskiren, at low doses, reduces the electrical remodeling in the heart of the TGR(mRen2)27 rat independently of blood pressure. J Renin Angiotensin Aldosterone Syst. Journal Renin Angiotensin Aldosterone System 2013; 14: 23-33.
29. Imanishi T, Ikejima H, Tsujioka H, et al. Addition of eplerenone to an angiotensin-converting enzyme inhibitor effectively improves nitric oxide bioavailability. Hypertension 2008; 51: 734-741.